Ukuqonda Olu hlobo lwe-Hepatitis C "Unyango"
Impendulo eqhubekayo ye-virologic (SVR ) kubantu abanesifo sokubulala i- hepatitis C kuthetha nje ukuba akukho bungqina bentsholongwane ye-hepatitis C (i-HCV) egazini labo emva kokuba befumene unyango lwe-hepatitis C. I-SVR yinjongo yokugqibela yonyango lwe-HCV kwaye, kwiimeko ezininzi, inokuthi ichazwe ngeklinikhi ngokuthi "yonyango" ukuba umthwalo we-HCV uhlala ungabonakaliyo kwiiveki ezingama-24 emva kokugqitywa kwonyango.
Phantse kuzo zonke iimeko, abantu abaneSVR yeeveki ezingama-24 abanakwenzeka ukuba bafumane isaphulelo se-viral (oko kukuthi, ukubuya kwegciwane). Uninzi uphando lubonisa ukuba iirhafu ezihlawulelwayo ziphantsi nje ngeepesenti ezi-1 ukuya kuma-2 ekhulwini kwiimeko ezinjalo.
Ukuchaza i-SVR kunye nezinye izimpendulo ze-Virologic
Emva kokuqaliswa kweyeza le-hepatitis C, igazi livavanywa ukulinganisa umsebenzi we-viral. Injongo ephambili kukuba kufezekiswe umthamo we-viral . "Akunakwenzeka," kulo mzekelo, akuthethi ukuba yintsi okanye ukungabikho ngokupheleleyo kwemisebenzi yentsholongwane emzimbeni; kunoko, ichazwa ngokungenayo intsholongwane ebonakalayo egazini usebenzisa ubuchwepheshe bokuhlola.
Isigaba ngasinye sempendulo sinikezwa udidi, kunye nezinye izigaba ezihambelanayo nomlinganiselo omncinci okanye ongaphantsi kwonyango. Jonga kule shredithi, ngezantsi.
| Ixesha | Nentsingiselo | Inkcazo | Prognosis |
| RVR | Impendulo yeVIV | Umthwalo ongenakubonakali wentsholongwane emva kweeveki ezine zonyango | Ngokubanzi amathuba okufikelela eSVR |
| eRVR | Ukuphendula ngokukhawuleza kwintsholongwane | Umthwalo ongenakulinganiswa wentsholongwane kwiveki 12, emva kweRVR yokuqala | Ngokubanzi amathuba okufikelela eSVR |
| EVR | Impendulo yokuqala yegciwane | Umthwalo ongenakulinganiswa wentsholongwane okanye i-99 ekhulwini yokunciphisa umthamo wentsholongwane ngeveki 12 | Ukungaphumeleli ukufezekisa i-EVR correlates ibe ngaphantsi kwama-4 ekhulwini amathuba okufikelela kwi-SVR |
| ETR | Ukuphela kwempendulo yonyango | Umthwalo wentsholongwane ongabonakali ufikelele ekupheleni kweveki 12 | Akukho luncedo ekuqikeleleni iziphumo zonyango |
| Mphendula | Iyakwazi ukufezekisa i-EVR kodwa ayikwazi ukugcina umthwalo wentsholongwane engabonakaliyo kwiiveki ezingama-24 emva kokupheliswa kweyeza | Kucatshangwa ukuhluleka kokonyango | |
| Umphenduli weNull | Ayikwazi ukufikelela kwi-EVR ngeveki 12 | Unyango lupheliswa ngokuqhelekileyo ukuba i-EVR ayiphumeli ngeveki 12 | |
| SVR | Impendulo yesifo segciwane | Unako ukugcina umthwalo wentsholongwane engabonakaliyo kwiiveki ezili-12 (i-SVR-12) kunye neeveki ezingama-24 (SVR-24) emva kokugqitywa kweyeza | I-SVR-24 ithathwa ngokuba "yonyango," kwaye izigulane ezine-SVR-12 zikwazi ukuphumeza i-SVR-24 |
Ukwandisa amathuba akho okuphumeza i-SVR
Esinye sezigqibo eziphambili zeempumelelo ze-SVR lixesha, kwaye unyango lwangaphambili luzuzisa izigulane ngaphezu kweyeza lokulibaziseka. Ngokuphatha intsholongwane ngaphambi kokuphawulwa komonakalo wesibindi (okanye, ngokwenene, nayiphi na umonakalo), ngokubanzi unethuba elingcono lokufumana unyango lwe-HCV.
Ukongezelela, i-anti-viral-acting anti-virus (DAAs) esandula ukuhamba ngokukhawuleza (ii-DAAs) ziye zaba nefuthe elibi kwimilinganiselo yokunyanga kubantu abanokusuleleka kwe-HCV. Kuma abantu abane- cirrhosis ehlawulwe , ababenamathuba okuba ngama-50/50 ithuba lokuphumelela unyango, amaxabiso e-SVR ayenyuke kancane ukuya kuma-95 ekhulwini kunye nangaphezulu kwiimeko ezininzi.
Izilingo zesigaba se-III ziqikelele oku kulandelwa kwezi zifo zonyango eziza kutshatyalaliswa (i-naïve) kunye nezigulane eziphathwe ngaphambili (ezizibonela) ezine-HCV:
- I-Daklinza (daclatasvir) isetyenziswe no-Sovaldi: ama-98 ekhulwini angama-naive kunye nama-58 ekhulwini anesifo se-cirrhosis
- IHarvoni (i-sofusbuvir + ledipasvir) : ipesenti ezingama-99 ze-naïve kunye nama-94 ekhulwini anamava
- I-Sovaldi ( sofosbuvir ) isetyenziswe kunye ne- ribavirin + peginterferon okanye i-ribavirin yedwa: 82 ukuya kwi-92 ekhulwini
- I-Technivie (ombitasvir + paritaprevir + ritonavir) : i- 99 ekhulwini i-naïve kunye namava
- I-Viekira Pak (ombitasvir + paritaprevir + ritonavir ehlanganiswe ne-dasabuvir) : iipesenti ezingama-95 ezinamava kunye namava
- I-Olysio (simeprevir) isetyenziswe ne-ribavirin + peginterferon: i- 80 ukuya kwe-85 ekhulwini
- I-Zepatier (grazoprevir + elbasvir) esetyenzisiweyo okanye ngaphandle kwe ribavirin: iipesenti ezingama-95 ezi-naïve kunye namava
Yintoni engaphumeleli ukuphumeza i-SVR
Nangona iinjongo ze-HCV unyango kukuphelisa intsholongwane kwaye ukuvumela umntu ukuba aphile ubomi obunempilo, obunobungozi be-hepatitis, isiguli akufanele sithembele ukuba akakwazi ukufezekisa ezi njongo.
Nangona unempendulo ekhethekileyo kuphela, uphando lubonise ukuba iingenelo zesibindi zinokuba lukhulu-kungekhona nje ukucotha inkqubo yesifo kodwa kwezinye iimeko ziguqula i-fibrosis, kwanabo abanomonakalo owenziwe ngesibindi.
Ukuba unokuncedisa unyango lwakho lokuqala okanye lwesibini, thatha ixesha lokujonga iziphumo zakho zegazi kunye nogqirha wakho. Ukuba uvakalelwa ukuba ulungele ukuzama kwakhona, ugqirha wakho angenza iimvavanyo eziliqela ukufumanisa ukuba iziphi iziyobisi ezingakunika ithuba elihle lokufumana impumelelo ye-SVR.
Ukujamelana ne-Hepatitis C
Ungavumeli ukusuleleka kwe-hepatitis C kukukwenza uzive ukhululekile. Kukho uncedo olukhoyo.
Ngaphandle kokucela abahlobo bakho namalungu omndeni ukuba akuncede ngexesha lokuhamba, unokufumana induduzo yokujoyina i-hepatitis C yoluntu kwi-intanethi okanye iqela elixhaphakileyo le-hepatitis. Kwakhona, ukufunda okuninzi malunga nesondlo esingasisigxina se-hepatitis kunokunceda uzive ungcono kwaye unokuphucula impendulo yakho yonyango.
> Imithombo:
> Chopra, S., noD. Muir. Imiqathango yokuLawula i-Hepatitis C engapheliyo kwi-Virus Genotype 1. UpToDate . Ukuhlaziywa 09/14/16.
> Kattakuzhy, S., Wilson, E., Sidharthan, S. et al. Iimali ezixhasayo ze-Virologic Impendulo kunye ne-6-Week Combination ngokukhawuleza eyenza i-Anti-Hepatitis C i-Virus Therapy kwizigulane ezinezifo eziphezulu. Izifo ezithathelwanayo . 2016. 62 (4): 440-7.
> Kattakuzhy, S., Wilson, E., Sidarthan, S. et al. Ukuguqulwa koMelana noTshintsho oluManyeneyo ngexesha loPhando lokuqala, ukusilela kweNtsholongwane, kunye noNyango ngokuSebenza ngokuCwangcisa ngokuCwangcisa i-Antiviral Treatment (NIH ISICELO SOKUSEBENZA). I-AASLD Intlanganiso yeSibindi; 2015; ezingabonakaliyo 220.
> Smith-Palmer, J., Cerri, K., kunye noW. Valentine. Ukufezekiswa kwempendulo ye-Virologic e-Hepatitis C: Ukuphononongwa ngokuchanekileyo kwe-Clinical, Economic and Quality of Benefits. Izifo ezithatheleneyo zeBMC . 2015. 15:19.